BEAM - Beam Therapeutics Inc - Stock & Dividends

Beam Therapeutics Inc. is a biotechnology company that focuses on developing precision genetic medicines to treat serious diseases in the United States. The company's primary goal is to create innovative treatments that can significantly improve the lives of patients suffering from debilitating conditions.

Beam Therapeutics has a robust pipeline of products in various stages of development. One of their lead candidates, BEAM-101, is being developed to treat sickle cell disease and beta-thalassemia, two severe genetic disorders that affect the production of hemoglobin. Another promising candidate, BEAM-302, is a liver-targeting formulation designed to treat severe alpha-1 antitrypsin deficiency, a rare genetic disorder that can lead to liver and lung disease.

In addition to these programs, Beam Therapeutics is also working on BEAM-201, an anti-CD7 CAR-T product candidate that is currently in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The company is also developing BEAM-301, a liver-targeting formulation to treat glycogen storage disease 1a, a rare genetic disorder that affects the body's ability to store and use sugar.

Beam Therapeutics has established several strategic research collaborations with leading biotechnology and pharmaceutical companies, including Pfizer Inc., Apellis Pharmaceuticals, Verve Therapeutics, Sana Biotechnology, and Orbital Therapeutics. These collaborations focus on developing innovative gene editing technologies, such as CRISPR Cas12b, to treat a range of rare genetic diseases affecting the liver, muscle, central nervous system, and cardiovascular system.

Founded in 2017, Beam Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to advancing the field of precision genetic medicine. The company's website can be found at https://beamtx.com.